BioMed Valley Discoveries announces first patient dosed in phase II combination trial with ulixertinib (BVD-523), its first-in-class and best-in-class ERK inhibitor, in combination with hydroxychloroquine
Kansas City, MO. – Sept. 12, 2022—BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a ...